What are the functions and effects of Quizartinib, and what is its price?

Quizartinib, trade name: Vanflyta, is an oral, highly effective II type FLT3 inhibitor, mainly used for treatmentFLT3-ITD (FMS-like tyrosine kinase3 internal tandem repeats)-positive acute myeloid leukemia (AML) in adult patients. This drug precisely targets the FLT3 kinase and inhibits its activity, thereby blocking the cell signaling pathway driven by the FLT3-ITD mutation, thereby inhibiting the proliferation and survival of leukemia cells.

FLT3-ITDmutation is one of the common molecular abnormalities in AML and is closely related to poor prognosis of the disease. The emergence of quizartinib provides new treatment hope for these patients. In clinical application, quizartinib has demonstrated significant therapeutic effects. It can significantly extend patients' progression-free survival (PFS) and overall survival (OS), and help some patients achieve complete remission (CR).

In addition to being used as monotherapy, quizartinib is often used in combination with standard chemotherapy regimens as induction and consolidation therapy in patients with newly diagnosed FLT3-ITDpositiveAML. This combined treatment regimen can further improve treatment effectiveness and reduce the risk of disease recurrence.

However, it is worth noting that the use of quizartinib is also accompanied by certain side effects and risks. Common side effects include nausea, vomiting, diarrhea, fatigue and other digestive and nervous system discomforts. In addition, serious side effects such as prolonged QT interval and abnormal liver function may occur. Therefore, when using quizartinib, doctors need to closely monitor the patient's physical condition and make dose adjustments and optimization of the treatment plan according to the patient's specific conditions.

Currently, Quizartinib has not yet been launched in China, so domestic patients cannot directly purchase this drug. It is reported that quizartinib has been launched overseas, including the original research version launched in Europe per box (17.7 mg (28 tablets) is priced at approximately 80,000 yuan, while the imitation version (17.7 mg (14 tablets)) available in Laos is priced at approximately 1,800 yuan.

In general, quizartinib is an effective targeted therapy for FLT3-ITDpositiveAML patients, and its emergence provides new treatment options and hope for these patients. However, you need to pay close attention to the side effects and risks during use and proceed under the guidance of a professional doctor.

xa0

Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC6081740/